PDS Biotechnology Corp.
NASDAQ: PDSB1 known investors
PDS Biotech develops targeted immunotherapies using its Versamune T cell activating platform and PDS01ADC technology to induce tumor-infiltrating T cell responses. The company focuses on cancer treatments and infectious disease vaccines that harness the immune system.